Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v2.4.0.6
Commitments and Contingencies (Details) (USD $)
 3 Months Ended
Mar. 31, 2013
Commitments and Contingencies (Textual) [Abstract]  
Percentage of number of shares of common stock equal to Base Shares 1.00%
UFRF [Member]
  
Commitments and Contingencies (Textual) [Abstract]  
License Agreement, Original Date Jun. 22, 2000
Company's obligation to pay from percentage of selling price of product 5.00%
Company's obligation to pay from all revenue received from sublicenses 22.00%
One-time commercialization fee would be due on the first anniversary of first commercial sale 5,000
Post-commercialization minimum royalty payments 50,000
One-time additional royalty payment would be due when total cumulative royalties 2,000,000
Total royalties due to UFRF 10.00%
License agreement amount 10,000
Minimum annual maintenance payments to UFRF 20,000
Quarterly maintenance payment to UFRF under installment plan 5,000
Intrexon [Member]
  
Commitments and Contingencies (Textual) [Abstract]  
License Agreement, Original Date Jun. 05, 2012
Percentage company pay on quarterly basis out of gross profit 25.00%
Company's obligation to make payment from all revenue received from sublicensing 50.00%
Period during which company cannot terminate license agreement voluntarily 18 months
Period during which company cannot terminate license agreement 12 months
Termination notice period 90 days
Number of shares issued 4,392,425
Maximum percentage of primary investment securities to investment of shares issued 10.00%
Intrexon [Member] | Filing of First Investigational New Drug Application [Member]
  
Commitments and Contingencies (Textual) [Abstract]  
Percentage of number of shares of common stock equal to Base Shares 2.50%
Intrexon [Member] | First Regulatory Approval of Oragenics Product [Member]
  
Commitments and Contingencies (Textual) [Abstract]  
Percentage of number of shares of common stock equal to Base Shares 3.00%
Intrexon [Member] | Clinical study Phase 2 [Member]
  
Commitments and Contingencies (Textual) [Abstract]  
Percentage of number of shares of common stock equal to Base Shares 1.50%
Intrexon [Member] | Clinical study Phase 3 [Member]
  
Commitments and Contingencies (Textual) [Abstract]  
Percentage of number of shares of common stock equal to Base Shares 2.00%
MU1140 [Member]
  
Commitments and Contingencies (Textual) [Abstract]  
License Agreement, First Amendment Date Sep. 15, 2000
License Agreement, Second Amendment Date Jul. 10, 2002
License Agreement, Third Amendment Date Sep. 25, 2002
License Agreement, Fourth Amendment Date Mar. 17, 2003
License Agreement Date Fifth Amended Apr. 19, 2013
Patents license expiration period 2017 through 2019
Smart Replacement Therapy [Member]
  
Commitments and Contingencies (Textual) [Abstract]  
License Agreement, Original Date Aug. 04, 1998
License Agreement, First Amendment Date Sep. 15, 2000
License Agreement, Second Amendment Date Jul. 10, 2002
License Agreement, Third Amendment Date Sep. 25, 2002
License Agreement, Fourth Amendment Date Mar. 17, 2003
License Agreement Date Fifth Amended Apr. 19, 2013
Patent right filling date Jun. 07, 1995
Patent effective date Mar. 04, 1997
Patent Right Expire Date Jun. 07, 2015